北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN HONG KONG PARIS MADRID SILICON VALLEY 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-020 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号中 心报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 上海益诺思生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 6 日 （一） 非累积投票议案 1、 议案名称：关于 2025 年度日常关联交易预计的议案 | 1、出席会议的股东和代理人人数 | 59 | | --- | --- | | 普通股股东人数 | 59 | | 2、出席会议的股东所持有的表决权数量 | 89,799,494 | | 普通股股东所持有表决权数量 | 89,799,494 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 63.6967 | | 例（%） | | ...

Core Viewpoint - The company, Yinos, is a leading contract research organization (CRO) in the non-clinical safety evaluation sector, providing comprehensive research services that align with both domestic and international standards, and has recently passed a GLP inspection by the FDA, enhancing its international service capabilities [25][26]. Company Overview - Yinos specializes in non-clinical research services for biopharmaceuticals, being one of the earliest companies in China to obtain GLP certifications from NMPA, OECD, and FDA, thus aligning with international standards [3][4]. - The company has a modern facility of nearly 60,000 square meters and a research team of over 1,000, with locations in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco [4]. - As of December 31, 2024, Yinos has served over 900 pharmaceutical companies and research institutions, contributing to numerous successful drug development cases [4][18]. Financial Performance - In the reporting period, Yinos achieved a revenue of RMB 1,141.67 million, representing a year-on-year growth of 9.94%, while the net profit attributable to shareholders decreased by 24% to RMB 147.78 million [23]. - The proposed profit distribution plan includes a cash dividend of RMB 3.2 per 10 shares, totaling RMB 45.11 million, which accounts for 30.53% of the net profit for the year [1]. Industry Context - The global CRO market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2026, with the market size expected to exceed USD 147.7 billion by 2030 [11]. - In China, the CRO service market is estimated to reach RMB 848.2 billion in 2023, with a projected CAGR of 9.9% from 2023 to 2026 [12]. - The industry is supported by government policies aimed at enhancing drug research and development capabilities, which is expected to drive long-term growth in the CRO sector [13][14]. Technological Advancements - Yinos is investing in artificial intelligence (AI) applications in non-clinical research, aiming to enhance efficiency and reduce costs in drug development processes [19]. - The company is also exploring organoid technology for drug screening and toxicity testing, which is gaining traction in the pharmaceutical research field [19][20]. Strategic Positioning - Yinos has established strong partnerships with leading pharmaceutical companies, positioning itself as a strategic partner in the innovative drug development process [18][21]. - The company is expanding its international presence, having established a subsidiary in the United States to enhance its global market share [22].

Group 1: Fund News - Yu Haichun has been appointed as the new chairman of Huafu Fund, succeeding Zhao Wanli who left due to work adjustments. Yu has 34 years of experience in the securities industry [1] - Morgan Fund plans to repurchase at least 54 million RMB of its newly launched equity public fund, committing to hold the investment for at least one year [1] - The total scale of public funds in China has remained above 32 trillion RMB for two consecutive months, with a net asset value of 32.22 trillion RMB as of March 31, 2025 [1] Group 2: Fund Manager Activities - Wan Minyuan's Rongtong Health Industry Fund has slightly reduced its holdings in Dongfang Biology, decreasing its share count by 489,000 shares compared to the end of last year [2] - Ge Lan's Zhongou Medical Health Mixed Fund has increased its position in Yinuosi, holding 403,100 shares, up from 99,500 shares at the end of last year, representing an increase of 303,600 shares [2] Group 3: ETF Market Overview - The market experienced fluctuations, with the Shanghai Composite Index down 0.23%, while the Shenzhen Component Index and the ChiNext Index rose by 0.51% and 0.83%, respectively. The total trading volume in both markets reached 1.17 trillion RMB, an increase of 147.2 billion RMB from the previous trading day [3] - AI-related ETFs on the Sci-Tech Innovation Board saw strong performance, with the highest increase reaching 4.30% [4] - Bank ETFs collectively declined, with the highest drop recorded at 2.19% [5] Group 4: ETF Investment Opportunities - Analysts suggest that despite increased market risk appetite, external disturbances remain. Domestic policies are expected to maintain stability, with potential for further reserve requirement ratio cuts and interest rate reductions, supporting bank valuations and credit conditions [6] Group 5: New Fund Launches - E Fund has launched the E Fund CSI Digital Economy Theme ETF, managed by Pang Yaping, which aims to track the performance of the CSI Digital Economy Theme Index [7] - Tianhong has introduced the Tianhong Guozheng Aerospace Industry ETF, managed by Sha Chuan, with a performance benchmark based on the Guozheng Aerospace Industry Index [10]

Core Viewpoint - The company, Yinos, reported a revenue of 1.142 billion yuan for the year 2024, reflecting a year-on-year growth of 9.94%, despite facing challenges in the CRO industry due to a slowdown in investment and market demand [1] Group 1: Financial Performance - The company's net profit attributable to shareholders was 148 million yuan, with a non-recurring net profit of 125 million yuan [1] - The growth in revenue was primarily driven by a 7.86% increase in revenue from the core safety evaluation service segment [1] - The company experienced a decline in gross margin due to intensified market competition and a decrease in order prices, influenced by a slowdown in the domestic pharmaceutical industry's investment and demand [1] Group 2: Industry Context - The CRO industry is facing a challenging year in 2024, characterized by reduced investment enthusiasm and slower-than-expected growth in the pharmaceutical market, leading to a complex environment of structural differentiation, accelerated integration, and policy-driven changes [1] - Despite these challenges, Yinos achieved a steady revenue increase, highlighting its strong sustainable development capabilities and risk resistance [1] Group 3: Business Development and Innovation - The company is actively building its "AI+" capabilities to drive business growth, focusing on the deep integration of artificial intelligence with industry scenarios [2] - In 2024, the company signed new orders amounting to 819 million yuan, with a 14.63% year-on-year increase in new orders for IND and NDA applications, demonstrating strong market expansion capabilities [2] - The company reported significant growth in new orders from overseas markets, indicating an increasing recognition and influence in international markets [2] - Yinos is continuously optimizing service processes, enhancing service quality, and strengthening technological research and development to address market challenges and improve resilience [2]

Core Insights - In 2024, the company achieved operating revenue of 1.142 billion yuan, representing a year-on-year growth of 9.94% [1] - The net profit attributable to shareholders was 148 million yuan, with a non-recurring net profit of 125 million yuan [1] Business Segments - The non-clinical CRO business generated revenue of 1.089 billion yuan, an increase of 8.99% year-on-year, with safety services contributing 959 million yuan, up 7.86% [1] - The clinical CRO business reported operating revenue of 46.9385 million yuan, reflecting a significant growth of 27.17% [1] New Orders and Market Position - In 2024, the company signed new orders amounting to 819 million yuan, with a backlog of 973 million yuan by the end of the year [1] - The number of new orders for new drug clinical trial applications and new drug marketing applications combined saw a year-on-year increase of 18.37% [1] Technological Advancements - The company has developed several core technology platforms, including toxicity biomarker evaluation and non-clinical safety evaluation systems, contributing to nearly 200 innovative drug research services [2] - The company is actively enhancing its "AI+" capabilities, focusing on the integration of artificial intelligence with industry scenarios, and exploring deep learning-based intelligent pathology diagnostic systems [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688710 证券简称：益诺思 公告编号：2025-016 上海益诺思生物技术股份有限公司 2024年度募集资金存放与使用情况的专项报告 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意上海益诺思生物技术股份有 限公司首次公开发行股票注册的批复》（证监许可〔2024〕762 号），上海益诺思 生物技术股份有限公司（以下简称"公司"、"益诺思"）首次公开发行人民币普 通股（A 股）3,524.4904 万股（以下简称"本次发行"），每股发行价格为人民 币 19.06 元，募集资金总额人民币 67,176.79 万元，主承销商国泰海通证券股份 有限公司（原海通证券股份有限公司，以下简称"保荐机构"）于 2024 年 8 月 29 日将扣除尚未支付的保荐及承销费 4,402.35 万元后的余款 62,774.44 万元汇入 募集资金专户中。扣除发行费用人民币 6,212.29 万元，募集资金净额为人民币 60,964.49 ...

经核查独立董事的任职经历以及相关自查文件，上述人员未在公司担任 除独立董事外的其他职务，并与公司及主要股东、实际控制人不存在直接 或者间接利害关系，或者其他可能影响其进行独立客观判断关系。 因此，公司独立董事满足独立董事的任职要求，不存在影响独立性的情 形符合《上市公司独立董事管理办法》中对独立董事独立性的相关规定。 上海益诺思生物技术股份有限公司 董事会对独立董事独立性自查情况的专项报告 上海益诺思生物技术股份有限公司（以下简称"公司"、"益诺思"） 董事会于近日收到公司在任独立董事李胜彩先生、邵蓉女士和范国钦先生 分别出具的《2024 年度独立董事独立性自查报告》，董事会对上述独立董 事的自查报告进行评估并出具如下专项意见： 上海益诺思生物技术股份有限公司董事会 2025 年 04 月 28 日 ...

上海益诺思生物技术股份有限公司 董事会审计委员会 2024 年度履职情况报告 根据中国证券监督管理委员会（以下简称"中国证监会"）《上市公司治理 准则》、《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》 以及《上海益诺思生物技术股份有限公司章程》（以下简称"《公司章程》"） 和《上海益诺思生物技术股份有限公司董事会审计委员工作细则》（以下简称 "《审计委员会工作细则》"）的规定，2024年度（以下简称"报告期"）内, 上海益诺思生物技术股份有限公司（以下简称"公司"）董事会审计委员会本着 勤勉尽责的原则，积极开展工作，认真履行职责。现就审计委员会2024年度履职 情况汇报如下： 审计委员会根据《审计委员会工作细则》的规定和相关监管要求，切实履 行了对公司财务报告的审阅工作，并对相关报告的编制提出了专业的意见和建 议。我们听取了会计师事务所对于公司财务报告的审计计划，就审计的总体计 划提出了具体意见和要求，并确定相关的时间安排，并要求审计机构应严格按 《中国注册会计师执业准则》开展审计工作，审计过程中若发现重大问题应及 时与审计委员会沟通。 2、监督及评估外部审计机构工作 审计委员会对公司聘请的立 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-019 上海益诺思生物技术股份有限公司 关于全资子公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海益诺思生物技术股份有限公司（以下简称"公司"）全资子公司益诺思生 物技术南通有限公司（以下简称"益诺思南通"）于2024年10月28日至2024年11 月1日期间接受了来自美国食品药品监督管理局（以下简称"FDA"）的良好实验 室规范（GLP）全面现场检查。 近日，公司收到FDA签发的现场检查报告（EIR，Establishment Inspection Report），该报告表明公司通过了本次美国FDA的GLP检查。现就相关情况公告 如下： 一、本次美国FDA现场检查相关情况 企业名称：益诺思生物技术南通有限公司 检查范围：组织机构及人员、设施设备及运行、质量保证体系、计算机化系 统管理、试验操作及管理等 检查地点：江苏省南通市海门区临江镇洞庭湖路 100 号 A18 楼 FDA FEI：3029550626 检查结论：通 ...